Download PDF
Thromb Haemost 1999; 81(04): 605-612
DOI: 10.1055/s-0037-1614533
Rapid Communication
Schattauer GmbH

Fibrin-specificity of a Plasminogen Activator Affects the Efficiency of Fibrinolysis and Responsiveness to Ultrasound: Comparison of Nine Plasminogen Activators In Vitro

Dmitry V. Sakharov
1   From the Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Marrie Barrett-Bergshoeff
1   From the Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Rob T. Hekkenberg
1   From the Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Dingeman C. Rijken
1   From the Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 03 September 1998

Accepted after revision 06 January 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

In a number of cases, thrombolytic therapy fails to re-open occluded blood vessels, possibly due to the occurrence of thrombi resistant to lysis. We investigated in vitro how the lysis of hardly lysable model thrombi depends on the choice of the plasminogen activator (PA) and is accelerated by ultrasonic irradiation. Lysis of compacted crosslinked human plasma clots was measured after addition of nine different PAs to the surrounding plasma and the effect of 3 MHz ultrasound on the speed of lysis was assessed.

Fibrin-specific PAs showed bell-shaped dose-response curves of varying width and height. PAs with improved fibrin-specificity (staphylokinase, the TNK variant of tissue-type PA [tPA], and the PA from the saliva of the Desmodus rotundus bat) induced rapid lysis in concentration ranges (80-, 260-, and 3,500-fold ranges, respectively) much wider than that for tPA (a 35-fold range). However, in terms of speed of lysis, these three PAs exceeded tPA only slightly. Reteplase and single-chain urokinase were comparable to tPA, whereas two-chain urokinase, anistreplase, and streptokinase were inferior to tPA. In the case of fibrin-specific PAs, ultrasonic treatment accelerated lysis about 1.5-fold. For streptokinase no acceleration was observed. The effect of ultrasound correlated with the presence of plasminogen in the outer plasma, suggesting that it was mediated by facilitating the transport of plasminogen to the surface of the clot.

In conclusion, PAs with improved fibrin-specificity induce rapid lysis of plasminogen-poor compacted plasma clots in much wider concentration ranges than tPA. This offers a possibility of using single-or double-bolus administration regimens for such PAs. However, it is not likely that administration of these PAs will directly cause a dramatic increase in the rate of re-opening of the occluded arteries since they are only moderately superior to tPA in terms of maximal speed of lysis. Application of high-frequency ultrasound as an adjunct to thrombolytic therapy may increase the treatment efficiency, particularly in conjunction with fibrin-specific PAs.

 

  • References

  • 1 Reddy KNN, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. J Biol Chem 1972; 247: 1683-91.
    PubMedGoogle Scholar
  • 2 Schick LA, Castellino FJ. Direct evidence for the generation of an active site in the plasminogen moiety of the streptokinase-human plasminogen activator complex. Biochem Biophys Res Commun 1974; 57: 47-54.
    CrossrefPubMedGoogle Scholar
  • 3 Monk JP, Heel RC. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 1987; 34: 25-49.
    CrossrefPubMedGoogle Scholar
  • 4 Lucas MA, Straight DL, Fretto LJ, McKee PA. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity. J. Biol. Chem 1983; 12171-7.
    PubMedGoogle Scholar
  • 5 Tennant SN, Dixon J, Venable TC, Page HL, Roach A, Kaiser AB. Intra-coronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation 1984; 69: 756-60.
    CrossrefPubMedGoogle Scholar
  • 6 Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-5.
    PubMedGoogle Scholar
  • 7 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
    PubMedGoogle Scholar
  • 8 Noorman F, Rijken DC. Regulation of tissue-type plasminogen activator concentrations by clearance via the mannose receptor and other receptors. Fibrinolysis & Proteolysis 1997; 11: 173-86.
    PubMedGoogle Scholar
  • 9 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. Engl J Med 1993; 329: 673-82.
    CrossrefPubMedGoogle Scholar
  • 10 Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguen H, Botstein D, Bennet WF. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-4.
    CrossrefPubMedGoogle Scholar
  • 11 Martin U, Mollendorff E, Akpan W. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis & Proteolysis 1997; 11: 129-35.
    PubMedGoogle Scholar
  • 13 Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.
    CrossrefPubMedGoogle Scholar
  • 14 Bringmann P, Gruber D, Liese A, Tochi L, Kratzschmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25556-603.
    PubMedGoogle Scholar
  • 15 Stewart RJ, Fredenburgh JC, Weitz I J. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998; 273: 18292-9.
    CrossrefPubMedGoogle Scholar
  • 16 de Munk GAW, Rijken DC. Fibrinolytic properties of single-chain urokinase-type plasminogen activator (pro-urokinase). Fibrinolysis 1990; 4: 1-9.
    PubMedGoogle Scholar
  • 17 Lijnen HR, Collen D. Staphylokinase, a fibrin-specific plasminogen activator. Fibrinolysis 1996; 10: 119-26.
    PubMedGoogle Scholar
  • 18 Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasmin(ogen) and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271: 27912-8.
    CrossrefPubMedGoogle Scholar
  • 19 Silence K, Collen D, Lijnen R. Regulation by α2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. Blood 1993; 82: 1175-83.
    PubMedGoogle Scholar
  • 20 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1983-7.
    PubMedGoogle Scholar
  • 21 Nishino N, Kakkar VV, Scully MF. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Thromb Haemost 1991; 66: 672-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Hauptmann J, Glusa E. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro. Blood Coagul Fibrinol 1995; 6: 579-83.
    CrossrefPubMedGoogle Scholar
  • 23 Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-90.
    CrossrefPubMedGoogle Scholar
  • 24 Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133-8.
    CrossrefPubMedGoogle Scholar
  • 25 Luo H, Nishioka T, Fishbein MC, Cercek B, Forrester JC, Kim CJ, Berglund H, Siegel RJ. Transcutaneous ultrasound augments lysis of arterial thrombi in vivo. Circulation 1996; 94: 775-8.
    CrossrefPubMedGoogle Scholar
  • 26 Francis CW, Onundarson PT, Carstenen EL, Blinc A, Meltzer RS, Schwarz K, Marder V. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest 1992; 90: 2063-8.
    CrossrefPubMedGoogle Scholar
  • 27 Lauer CG, Burge R, Tang DB, Bass BG, Gomez ER, Alving BM. Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis. Circulation 1992; 86: 1257-64.
    CrossrefPubMedGoogle Scholar
  • 28 Blinc A, Francis CW, Trudnovski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood 1993; 81: 2636-43.
    PubMedGoogle Scholar
  • 29 Kashyap A, Blinc A, Marder VJ, Penney DP, Francis CW. Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res 1994; 76: 475-85.
    CrossrefPubMedGoogle Scholar
  • 30 Siddiqi F, Blinc A, Braaten J, Francis CW. Ultrasound increases flow through fibrin gels. Thromb Haemost 1995; 73: 495-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 1997; 78: 1063-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Siddiqi F, Odrlijn TM, Fay PJ, Cox C, Francis CW. Binding of tissue-type plasminogen activator to fibrin: effect of ultrasound. Blood 1998; 91: 2019-25.
    PubMedGoogle Scholar
  • 33 Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 1995; 3: 419-24.
    PubMedGoogle Scholar
  • 34 Robbins KC, Barlow GH, Nguyen G, Samama MM. Comparison of plasminogen activators. Semin Thromb Hemost 1987; 13: 131-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Hekkenberg RT, Reibold R, Zegiri B. Development of standard measurement methods for essential properties of ultrasound therapy equipment. Ultrasound Med Biol 1994; 20: 83-98.
    CrossrefPubMedGoogle Scholar
  • 36 Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorragic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood 1982; 59: 1169-80.
    PubMedGoogle Scholar
  • 37 Verstraete M, Bounameaux H, De Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in man. J Pharmacol Exp Therapeut 1985; 235: 506-12.
    PubMedGoogle Scholar
  • 38 Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
    CrossrefPubMedGoogle Scholar
  • 39 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
    CrossrefPubMedGoogle Scholar
  • 40 Barbagelata NA, Granger CB, Oqueli E, Suarez LD, Borruel M, Topol EJ, Califf RM. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J 1997; 133: 273-82.
    CrossrefPubMedGoogle Scholar
  • 41 Jang IK, Gold HK, Ziskind AA, Fallon JT, Leinbach RC, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombosis. Circulation 1989; 79: 920-8.
    CrossrefPubMedGoogle Scholar
  • 42 Kunitada S, Fitzgerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-7.
    PubMedGoogle Scholar
  • 43 Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 1990; 64: 450-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-50.
    CrossrefPubMedGoogle Scholar
  • 45 Sobel BE, Nachowiak DA, Fry ETA, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coronary Artery Dis 1990; 1: 111-9.
    CrossrefPubMedGoogle Scholar
  • 46 The COBALT Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337: 1124-30.
    CrossrefPubMedGoogle Scholar
  • 47 The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
    CrossrefPubMedGoogle Scholar
  • 48 Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Fox NL, Braunwald E. and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95: 351-6.
    CrossrefPubMedGoogle Scholar
  • 49 Vanderschueren S, Dens J, Kerdsinchai P, Desmet W, Vrolix M, de Man F, van den Heuvel P, Hermans L, Collen D, van der Werf F. A randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997; 134: 213-9.
    CrossrefPubMedGoogle Scholar
  • 50 Riggs PN, Francis CW, Bartos SR, Penney DP. Ultrasound enhancement of rabbit femoral artery thrombolysis. Cardiovasc Surg 1997; 5: 201-7.
    CrossrefPubMedGoogle Scholar